U.s. fda grants regular approval and expands indication for padcev® (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer

Tokyo and bothell, wash., july 9, 2021 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d.

SGEN Ratings Summary

SGEN Quant Ranking